Quantcast

Local Physicians Present Innovative Cancer Research Findings at National Conference

June 4, 2011

Texas Oncology Research Showcased at American Society of Clinical Oncologists Annual Meeting

Dallas, TX (PRWEB) June 03, 2011

Twenty-two Texas Oncology physicians have contributed research findings to the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, which opened June 3. The international event features the latest research breakthroughs and treatment advances from physicians around the world, attracting more than 30,000 members of the oncology community each year.

Texas Oncology’s findings, which focus on leading-edge treatments for cancers of the breast, prostate, pancreas, colon, and others, were selected as part of a competitive peer-review process. While inclusion in the conference is an esteemed honor itself, ASCO also distinguishes leading research with its “Best of ASCO” recognition, which highlights potential game-changers in the cancer care industry. Two Texas Oncology physicians, Drs. Joyce O’Shaughnessy (Dallas) and Frankie Holmes (Houston) were recognized as part of the “Best of ASCO” honor for their separate research related to breast cancer.

“Texas Oncology’s research, often conducted in partnership with other medical centers, took place locally with Texas-based patients, demonstrating that impactful research is not just taking place at large medical centers and universities, but also at community-based private practices like Texas Oncology,” said Dr. Steven Paulson, president and chairman of the board of Texas Oncology.

Texas Oncology’s commitment to research is strong, having played an integral role in developing 43 cancer-fighting drugs approved by the FDA. The latest drug was approved in April 2011 to treat advanced prostate cancer. Texas Oncology’s Dr. Thomas Hutson (Dallas) played a key role in the clinical trials for the new first-in-its-class drug, abiraterone acetate. It was recently featured in the New England Journal of Medicine.

As the most significant cancer meeting of the year, ASCO highlights the ongoing importance of cancer research and its impact on all generations of cancer patients. Many of the research abstracts presented at this year’s ASCO meeting will lead to additional treatment options and advanced exploration of cancer-fighting therapies to help cancer patients in the future.

“The research unveiled at ASCO now could have a significant impact on what cancer treatments are available in the future,” Dr. Paulson said. “In recent years, great treatment advancements have been made resulting in fewer side effects and improved quality of life.”

The Importance of Clinical Trials

The research findings presented at ASCO are based on a series of completed and ongoing clinical trials, which are a critical component in the fight against cancer. Trials advance medical research and identify breakthrough treatments, and with the help of patient volunteers, clinical trials examine how participants respond to different medical approaches for various types of cancers.

The results of clinical trials bring lifesaving new drugs, better cancer screenings, and cancer prevention options to the general population, enhancing treatment options and overall care.

While the volunteer participation in clinical trials may lead to breakthrough treatments and better quality of life for future patients, less than five percent of adult cancer patients will enroll in a clinical trial, according to the American Cancer Society. Despite this low participation, the clinical trial process is a simple one, and may lead to benefits for trial participants.

In 2010, more than 1,200 Texas Oncology patients voluntarily participated in 59 different clinical trials at Texas Oncology cancer centers and practices across the state, including trials for prostate, breast, lung, and skin cancers. For more information about clinical trials, click here.

“Clinical trials play a huge role in the advancement of patient care,” said Dr. Paulson. “The Texas Oncology research featured at ASCO represents huge strides in identifying new treatment options, and our local patients who participated in those trials have contributed greatly to cancer research.”

Texas Oncology Research at ASCO

The following Texas Oncology physicians contributed to ASCO presentations:

  • Drs. Joanne Blum (Dallas), Barry Brooks (Dallas), Frankie Ann Holmes (Houston), Russell Hoverman (Austin), Lea Krekow (Bedford and Grapevine), Kristi McIntyre (Dallas), Joyce O’Shaughnessy (Dallas), Cindy Osborne (Dallas), Debra Patt (Austin), John Pippen (Dallas), Ragene Rivera (El Paso), Christopher Stokoe (Plano), and Svetislava Vukelja (Tyler) contribute separate and collective research about breast cancer.
  • Drs. Frankie Holmes and Joyce O’Shaughnessy will present separate presentations about breast cancer treatments that are among the conference’s “Best in ASCO” selections.
  • Dr. Thomas Hutson (Dallas) provides research updates about melanoma, prostate, and kidney cancers.
  • Dr. Michael Teneriello (Austin and Waco) supplies research for gynecologic cancers.
  • Dr. Guru Sonpavde (Houston) provides research findings for prostate, bladder, and urothelial cancers.
  • Dr. Donald Richards (Tyler) supplies research for stomach and pancreatic cancers.
  • Drs. Darren Kocs (Round Rock and Cedar Park), David McCollum (Dallas), and Donald Richards provide research updates for stomach and gastroesophageal cancers.
  • Dr. Carlos Becerra (Dallas) will provide study results related to colorectal and pancreatic cancers.
  • Dr. Sanjay Awasthi (Arlington South) supplies clinical trial findings related to prostate cancer.
  • Dr. Kevin Doner (Austin and Cedar Park) provides clinical research findings for lymphoma.

Three Texas Oncology physicians, Drs. Steven Paulson, Thomas Hutson, and John Pippen will serve as chairs and/or speakers at education and special sessions during the conference.

About Texas Oncology

Texas Oncology delivers high-quality cancer care with leading-edge technology and advanced treatment and therapy options available to help patients achieve “More breakthroughs. More victories.”® in their fights against cancer, right in their own communities. Texas Oncology, a pioneer in community-based cancer care, is an independent oncology practice with sites of service throughout Texas, southern New Mexico, and southeastern Oklahoma. Texas Breast Specialists and Texas Urology Specialists, which focus on all areas of breast and urologic care, are a part of Texas Oncology.

Texas Oncology patients have the opportunity to take part in some of the most promising clinical trials in the nation for a broad range of cancers. Through its affiliation with US Oncology and the US Oncology Research network, Texas Oncology participates in innovative clinical trials from Phase I through Phase IV, and has played a role in the development of 43 Food and Drug Administration (FDA) approved cancer therapies.

Texas Oncology is united in healing with US Oncology, Inc., a division of McKesson Corporation. US Oncology unites the nation’s largest community-based cancer treatment and research network. As an affiliate of the United Network of US Oncology, physicians and clinicians at Texas Oncology are united with more than 1,100 physicians and 10,000 cancer professionals from across the country.

For more information, visit http://www.TexasOncology.com or call 1-888-864-I CAN (4226).

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebascoconference/cancerresearch/prweb8524948.htm


Source: prweb



comments powered by Disqus